– CG210™ improves hair thickness in patients using finasteride –
Legacy Healthcare, a company developing innovative products for hair and scalp disorders with a special focus on oncology supportive care, today announced clinical results of a double-blind, placebo-controlled, long-term trial of its innovative CG210™ topical treatment in patients suffering from hair loss.
The primary endpoint of the 12-month clinical study in subjects already using finasteride 1mg as a treatment for hair loss was the increase of mean diameter of hair. Participants received topical CG210™ or topical placebo in addition to the oral finasteride 1mg they were already taking. Finasteride, a synthetic type-2 5α-reductase inhibitor, has been approved by the US FDA, among others, for the treatment of male pattern baldness (MPB). As of September 27, 2012, results from 16 volunteers, who completed a 12 month cycle, were analyzed. The mean diameter of hair of subjects receiving topical CG210 increased 36.9% more than the mean diameter of hair of subjects receiving topical placebo (p<0,0001). The study was conducted in Japan.